Non-Small Cell Lung Cancer Therapeutics Market, By Therapy (Targeted Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel, By Cancer Type, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4079
|
Published Date
June 2025
|
Pages
288
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Non-Small Cell Lung Cancer Therapeutics Market size was valued at US$ 21,461.20 Million in 2024, expanding at a CAGR of 12.99% from 2025 to 2032.
Non-small cell lung cancer (NSCLC) therapeutics encompass a broad range of pharmacological and interventional treatments designed for lung cancers that are not classified as small cell lung cancer. The treatment landscape for NSCLC has evolved significantly, moving beyond traditional chemotherapy to include targeted therapies that focus on specific genetic mutations within tumor cells, as well as immunotherapies that harness the body’s immune system to combat cancer. These therapies work by inhibiting cancer cell growth, inducing apoptosis (programmed cell death), and preventing metastasis. The choice of therapeutic approach depends on several factors, including the histological subtype of NSCLC, the stage of cancer at diagnosis, the presence of particular biomarkers, and the overall health condition of the patient. The primary objectives of NSCLC treatment are to extend patient survival, enhance quality of life, and alleviate symptoms caused by the disease.
Non-Small Cell Lung Cancer Therapeutics Market- Market Dynamics
The market for non-small cell lung cancer (NSCLC) therapeutics is primarily driven by the increasing global incidence of lung cancer, fueled by persistent smoking habits and rising environmental pollution. Lung cancer remains one of the leading causes of cancer-related deaths worldwide, as reported by the World Health Organization (WHO), which estimates that lung cancer accounts for approximately 18% of all cancer deaths globally. Advances in understanding the molecular biology of NSCLC have paved the way for the development of targeted therapies and immunotherapies, offering more precise and potentially less toxic treatment options. Ongoing research into new biomarkers and therapeutic targets holds promise for the advancement of personalized medicine approaches. Combining immunotherapy with targeted agents has shown encouraging results, particularly in improving outcomes for patients with advanced stages of the disease. Additionally, the adoption of advanced diagnostic techniques, such as liquid biopsies, allows for earlier detection and real-time monitoring of treatment response, facilitating more effective and timely interventions. Growth in healthcare infrastructure and increased access to sophisticated cancer treatments in emerging markets present further opportunities for market expansion.
Governments and international health organizations are actively supporting lung cancer initiatives. For example, the U.S. Food and Drug Administration (FDA) has accelerated approval pathways for innovative NSCLC therapies to expedite patient access. Similarly, the European Medicines Agency (EMA) promotes research through funding and streamlined regulations to support the development of targeted and immunotherapies. The WHO also advocates for global tobacco control policies, recognizing smoking cessation as a critical factor in lung cancer prevention. However, the high cost of many novel therapies, especially targeted treatments and immunotherapies, remains a significant barrier to access for a large portion of the global patient population. Moreover, complex regulatory requirements and prolonged approval processes for new drugs can impede the pace of market growth.
Non-Small Cell Lung Cancer Therapeutics Market- Key Insights
- Targeted therapy holds a substantial market share due to its high effectiveness in treating specific molecular subtypes of NSCLC, particularly adenocarcinoma, the most common histologic subtype. The success of targeted drugs against mutations such as EGFR and ALK has established targeted therapy as a cornerstone of NSCLC treatment, significantly improving progression-free survival for patients with these genetic alterations.
- Immunotherapy is experiencing the fastest growth during the forecast period, driven by its ability to provide durable responses and long-term survival benefits, even in advanced stages of the disease. The expanding use of immune checkpoint inhibitors—both as monotherapy and in combination with chemotherapy or targeted therapies—across various NSCLC subtypes and stages is a key factor fueling this rapid expansion.
- Online pharmacies are projected to be the fastest-growing distribution channel for NSCLC therapeutics. This growth is supported by the increasing convenience, accessibility, and often cost-effectiveness of purchasing medications online. Additionally, the rising adoption of telemedicine and remote healthcare services further boosts the demand for online pharmacies, particularly for oral NSCLC treatments.
- Adenocarcinoma accounted for the largest market share, as it is the most prevalent histological subtype of NSCLC worldwide and frequently harbors genetic mutations that are targetable with currently available therapies. Its high prevalence, combined with effective targeted treatment options, has made adenocarcinoma a dominant segment in the NSCLC therapeutics market.
Non-Small Cell Lung Cancer Therapeutics Market- Segmentation Analysis:
The Global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Therapy, Distribution Channel, Cancer Type, and Region.
The market for non-small cell lung cancer (NSCLC) therapies is segmented by treatment type into targeted therapy, immunotherapy, and chemotherapy. Targeted therapy holds the largest market share, driven by significant advances in understanding the molecular mechanisms behind NSCLC. Identification of oncogenic drivers such as EGFR, ALK, ROS1, and BRAF mutations has enabled the development and approval of highly effective targeted drugs. These therapies, especially beneficial for patients with adenocarcinoma, typically offer greater efficacy and fewer side effects compared to traditional chemotherapy. According to the U.S. National Cancer Institute (NCI), targeted therapies have improved five-year survival rates for NSCLC patients with specific mutations by up to 30%, underscoring their critical role in current treatment protocols.
Immunotherapy represents the fastest-growing segment in the NSCLC treatment market, propelled by breakthroughs in immune checkpoint inhibitors. These drugs have demonstrated the ability to produce durable responses and extend long-term survival for many patients across various NSCLC subtypes. The U.S. Food and Drug Administration (FDA) has expanded immunotherapy indications to include earlier stages of NSCLC and combination regimens with chemotherapy and targeted agents, which is accelerating adoption globally. Government-supported clinical trials and accelerated approval pathways continue to fuel innovation and accessibility in this segment, significantly impacting patient outcomes.
When considering distribution channels, the NSCLC drug market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies dominate the market share due to the need for specialized infrastructure to administer complex intravenous treatments such as chemotherapy and many immunotherapies. These settings also provide access to highly trained healthcare professionals necessary for safe treatment delivery and monitoring. The Centers for Medicare & Medicaid Services (CMS) reports that over 70% of chemotherapy administrations in the U.S. occur in hospital outpatient settings, highlighting the critical role of hospital pharmacies in NSCLC care. Conversely, online pharmacies are the fastest-growing channel, benefiting from increased e-commerce adoption and patient preference for convenience. Online platforms provide easy access to oral targeted therapies and supportive care medications at competitive prices, with home delivery options, which is especially valuable for lung cancer patients managing long-term treatment regimens. Regulatory bodies like the FDA and Drug Enforcement Administration (DEA) have implemented guidelines to ensure the safety and authenticity of medications distributed via online pharmacies, fostering trust and market expansion.
Non-Small Cell Lung Cancer Therapeutics Market- Competitive Landscape:
The non-small cell lung cancer (NSCLC) therapeutics market is highly competitive, featuring established pharmaceutical and biotech giants alongside emerging entrants. Leading companies such as Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, AstraZeneca, Pfizer Inc., Bristol Myers Squibb, and Merck Sharp & Dohme Corp. dominate the market with extensive portfolios of approved treatments, strong research and development capabilities, and well-established global distribution networks. These firms are actively developing new targeted therapies, immunotherapies, and combination regimens to meet the evolving needs of NSCLC patients and to overcome treatment resistance. Strategic collaborations, licensing agreements, and acquisitions have intensified competition by expanding product pipelines and market reach. Innovation remains a key differentiator, with companies focusing on identifying new therapeutic targets, developing next-generation inhibitors, and exploring novel treatment modalities such as antibody-drug conjugates and cell therapies. The growing emphasis on personalized medicine and biomarker-driven treatments further fuels competition, as firms invest heavily in companion diagnostics to identify patient populations most likely to benefit from their therapies.
Recent Developments:
- December 2024: AstraZeneca and Daiichi Sankyo submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for datopotamab deruxtecan (Dato-DXd) as a treatment for adult patients with unresectable or metastatic non-squamous NSCLC previously treated with other therapies.
- October 2023: Eli Lilly and Company received FDA approval for selpercatinib (Retevmo) to treat adult patients with locally advanced or metastatic NSCLC harboring RET fusion-positive tumors, as detected by an FDA-approved test. This approval adds a targeted therapy option for this specific molecular subtype.
- June 2023: Bristol Myers Squibb announced FDA approval of Opdivo (nivolumab) combined with platinum-doublet chemotherapy as neoadjuvant therapy, followed by adjuvant nivolumab monotherapy, for adult patients with resectable NSCLC (tumors ≥4 cm or node-positive). This regimen offers an additional immunotherapy option in the perioperative setting for patients with more advanced resectable disease.
- May 2023: Astellas partnered with a biotech company to develop novel antibody-drug conjugates targeting multiple cancers, including NSCLC. This collaboration combines Astellas’ antibody engineering expertise with the partner’s proprietary payload technology to create more effective, targeted lung cancer therapies.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Novartis AG
- Astellas
- Bristol Myers Squibb
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Millennium Pharmaceuticals, Inc. (Takeda)
- Merck Sharp & Dohme Corp.
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY - MARKET ANALYSIS, 2019 - 2032
- Targeted Therapy
- Immunotherapy
- Chemotherapy
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL - MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Non-Small Cell Lung Cancer Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Therapy
2.1.2. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Distribution Channel
2.1.3. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Cancer Type
2.1.4. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Country
2.1.5. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Non-Small Cell Lung Cancer Therapeutics Key Market Trends
3.1. Non-Small Cell Lung Cancer Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Non-Small Cell Lung Cancer Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Non-Small Cell Lung Cancer Therapeutics Market Opportunities
3.4. Non-Small Cell Lung Cancer Therapeutics Market Future Trends
4. Non-Small Cell Lung Cancer Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Non-Small Cell Lung Cancer Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Non-Small Cell Lung Cancer Therapeutics Market Landscape
6.1. Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Non-Small Cell Lung Cancer Therapeutics Market – By Therapy
7.1. Overview
7.1.1. Segment Share Analysis, By Therapy, 2024 & 2032 (%)
7.1.2. Targeted Therapy
7.1.3. Immunotherapy
7.1.4. Chemotherapy
8. Non-Small Cell Lung Cancer Therapeutics Market – By Distribution Channel
8.1. Overview
8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
8.1.2. Hospital Pharmacies
8.1.3. Retail Pharmacies
8.1.4. Online Pharmacies
9. Non-Small Cell Lung Cancer Therapeutics Market – By Cancer Type
9.1. Overview
9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
9.1.2. Adenocarcinoma
9.1.3. Squamous Cell Carcinoma
9.1.4. Large Cell Carcinoma
10. Non-Small Cell Lung Cancer Therapeutics Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Non-Small Cell Lung Cancer Therapeutics Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
11.2.2. Eli Lilly and Company
11.2.3. Celgene Corporation
11.2.4. AstraZeneca
11.2.5. Pfizer Inc.
11.2.6. Sanofi
11.2.7. Novartis AG
11.2.8. Astellas
11.2.9. Bristol Myers Squibb
11.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
11.2.11. Millennium Pharmaceuticals, Inc. (Takeda)
11.2.12. Merck Sharp & Dohme Corp.
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
